Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3742941rdf:typepubmed:Citationlld:pubmed
pubmed-article:3742941lifeskim:mentionsumls-concept:C0023206lld:lifeskim
pubmed-article:3742941lifeskim:mentionsumls-concept:C0011847lld:lifeskim
pubmed-article:3742941lifeskim:mentionsumls-concept:C0301625lld:lifeskim
pubmed-article:3742941pubmed:issue4lld:pubmed
pubmed-article:3742941pubmed:dateCreated1986-10-6lld:pubmed
pubmed-article:3742941pubmed:abstractTextThe effect of immunomodulatory lectins on diabetes development following low-dose streptozotocin treatment in inbred mice was studied. All lectins administered had been shown previously to suppress immune reactivity. Among plant lectins concanavalin A but not Lens culinaris or wheat germ agglutinin partially suppressed hyperglycaemia following low-dose streptozotocin. A similar inhibitory effect was found for the staphylococcal enterotoxin B. Finally, administration of an immunomodulatory lectin from vertebrates, electrolectin, also had a beneficial effect on the course of the disease. These findings indicate that some lectins have a suppressive effect on Type 1 diabetes in an animal model.lld:pubmed
pubmed-article:3742941pubmed:languageenglld:pubmed
pubmed-article:3742941pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3742941pubmed:citationSubsetIMlld:pubmed
pubmed-article:3742941pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3742941pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3742941pubmed:statusMEDLINElld:pubmed
pubmed-article:3742941pubmed:monthMaylld:pubmed
pubmed-article:3742941pubmed:issn0265-5985lld:pubmed
pubmed-article:3742941pubmed:authorpubmed-author:KolbHHlld:pubmed
pubmed-article:3742941pubmed:authorpubmed-author:KieselUUlld:pubmed
pubmed-article:3742941pubmed:authorpubmed-author:RoosPPlld:pubmed
pubmed-article:3742941pubmed:authorpubmed-author:SchwanIIlld:pubmed
pubmed-article:3742941pubmed:authorpubmed-author:GreulichBBlld:pubmed
pubmed-article:3742941pubmed:authorpubmed-author:OschilewskiMMlld:pubmed
pubmed-article:3742941pubmed:issnTypePrintlld:pubmed
pubmed-article:3742941pubmed:volume3lld:pubmed
pubmed-article:3742941pubmed:ownerNLMlld:pubmed
pubmed-article:3742941pubmed:authorsCompleteYlld:pubmed
pubmed-article:3742941pubmed:pagination183-6lld:pubmed
pubmed-article:3742941pubmed:dateRevised2007-9-11lld:pubmed
pubmed-article:3742941pubmed:meshHeadingpubmed-meshheading:3742941-...lld:pubmed
pubmed-article:3742941pubmed:meshHeadingpubmed-meshheading:3742941-...lld:pubmed
pubmed-article:3742941pubmed:meshHeadingpubmed-meshheading:3742941-...lld:pubmed
pubmed-article:3742941pubmed:meshHeadingpubmed-meshheading:3742941-...lld:pubmed
pubmed-article:3742941pubmed:meshHeadingpubmed-meshheading:3742941-...lld:pubmed
pubmed-article:3742941pubmed:meshHeadingpubmed-meshheading:3742941-...lld:pubmed
pubmed-article:3742941pubmed:meshHeadingpubmed-meshheading:3742941-...lld:pubmed
pubmed-article:3742941pubmed:meshHeadingpubmed-meshheading:3742941-...lld:pubmed
pubmed-article:3742941pubmed:meshHeadingpubmed-meshheading:3742941-...lld:pubmed
pubmed-article:3742941pubmed:year1986lld:pubmed
pubmed-article:3742941pubmed:articleTitleSuppression of low-dose streptozotocin-induced diabetes by immunomodulatory lectins.lld:pubmed
pubmed-article:3742941pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3742941pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed